Boston Scientific Co. (NYSE:BSX) Shares Purchased by iA Global Asset Management Inc.

iA Global Asset Management Inc. increased its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 6.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 180,367 shares of the medical equipment provider's stock after buying an additional 10,840 shares during the period. iA Global Asset Management Inc.'s holdings in Boston Scientific were worth $16,110,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. TFC Financial Management Inc. grew its position in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. Dunhill Financial LLC grew its holdings in Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 152 shares during the last quarter. Global Wealth Strategies & Associates increased its position in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after buying an additional 250 shares in the last quarter. West Oak Capital LLC acquired a new position in shares of Boston Scientific in the fourth quarter worth $29,000. Finally, Valley National Advisers Inc. lifted its position in shares of Boston Scientific by 262.4% in the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 286 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Boston Scientific Stock Up 2.0 %

Shares of BSX stock traded up $2.05 on Monday, hitting $102.74. The stock had a trading volume of 5,830,086 shares, compared to its average volume of 5,772,590. Boston Scientific Co. has a 52-week low of $66.80 and a 52-week high of $107.17. The firm has a market capitalization of $151.96 billion, a price-to-earnings ratio of 82.19, a P/E/G ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock's 50 day moving average is $101.84 and its 200-day moving average is $92.65.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the completion of the transaction, the executive vice president now directly owns 25,443 shares of the company's stock, valued at $2,704,845.33. This trade represents a 4.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares of the company's stock, valued at $560,103.60. The trade was a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 137,302 shares of company stock worth $14,319,269 in the last 90 days. 0.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

BSX has been the subject of a number of recent research reports. JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research report on Monday, December 16th. Piper Sandler lifted their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Canaccord Genuity Group upped their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Argus set a $130.00 target price on shares of Boston Scientific in a research note on Tuesday, February 18th. Finally, Barclays raised their price objective on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.